NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
NIH StrokeNet seeks clinical trials and biomarker studies for stroke treatment, recovery, and prevention, offering infrastructure support for selected projects.
Browse similar grants
Funder: National Institutes of Health
Due Dates: November 19, 2026 (Resubmission / Revision; final closing date)
Funding Amounts: No budget cap; UG3 up to 1 year, followed by UH3 typically 4 years (up to 6 with strong justification)
Summary: Supports multi-site stroke clinical trials, trial-ready biomarker and outcome validation, and ancillary studies conducted through NIH StrokeNet.
Key Information: Prior NINDS approval is required for every application, regardless of budget; existing StrokeNet membership is not required.
Description
The National Institute of Neurological Disorders and Stroke (NINDS) supports exploratory and confirmatory multi-site studies through NIH StrokeNet, its clinical trials research network. This opportunity covers promising interventions for stroke prevention, acute treatment, recovery, and rehabilitation in pediatric and adult patients. It also supports biomarker or clinical outcome validation immediately preparatory to trials and ancillary studies adding scientific aims to active StrokeNet studies. Biomarker discovery is not supported.
Awards use a milestone-driven UG3/UH3 cooperative agreement, beginning with planning and start-up before possible transition to implementation. Applicants collaborate with StrokeNet on feasibility, research plans, and budgets. The network provides central coordination, statistical and data management support, recruitment and retention support, and clinical-site implementation. Applications must address both phases, including project management and performance milestones.
